Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(interferon beta 1a)
1,990 results
  • Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. [Journal Article]
  • NeurNeurology 2016 Oct 4; 87(14):1464-1472
  • Arnold DL, Fisher E, … CARE-MS I and CARE-MS II Investigators
  • CONCLUSIONS: Alemtuzumab demonstrated greater efficacy than SC IFN-β-1a on MRI endpoints in active RRMS. The superiority of alemtuzumab was more prominent during the second year of both studies. These findings complement the superior clinical efficacy of alemtuzumab over SC IFN-β-1a in RRMS.
New Search Next